Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

Fox Chase Cancer Center, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Philadelphia, PA
Treatments:Biologic therapyHospital:Fox Chase Cancer Center
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 2 study involved previously treated advanced urothelial tract carcinoma patients who were divided into two separated treatment groups. Group A consisted of 11 patients with a median age of 70 years; 9 were male. Group B had 28 patients with a median age of 69 years; 21 were male.

Treatment:
Patients in group A were treated with the biologic therapy agent cetuximab, which is a monoclonal antibody that targets cancer cells to be killed by the immune system.

Patients in group B were treated with cetuximab and the chemotherapy agent paclitaxel.

Toxicities:
The maximum toxicity grade in group A was grade 4 and included grade 3-4 rash, diarrhea, and fatigue.

Treatment-related deaths were reported in group B but specific causes were not given. Grade 3-4 rash, fatigue, and low magnesium levels were also reported.

Results:
The median overall survival rates for groups A and B were 3.9 and 9.7 months, respectively.

Support:
This study was partially supported by Bristol Myers Squibb.

Correspondence: Dr. Yu-Ning Wong; email: [email protected]



Back